Navigation Links
WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Date:3/1/2011

to come."  

The 18-month study will determine patients' rates of warfarin-related adverse events at 30, 60 and 90 days from initial warfarin dosing.  Study results will be used by CMS for reimbursement decision-making.  The multicenter, randomized, blinded, parallel-group study is being led by Principal Investigator Elizabeth Ofili, M.D., Chief of Cardiology, Director of Clinical Research, and Associate Dean for Clinical Research at Morehouse School of Medicine.  Trial registration and study sites can be found at www.warfarinstudy.org.  

"This landmark study is about more than warfarin," said Dean Sproles, CEO and Chairman, Iverson Genetic Diagnostics Inc., which initiated the WARFARIN Study.  "It is about individualizing treatment to improve patient safety and outcomes, thereby reducing healthcare costs.  CMS' support of the WARFARIN Study demonstrates their commitment to exploring the impact of genetic testing on individualized dosing, which may pave the way for other studies in the personalized medicine arena."

About Iverson Genetic Diagnostics, Inc.Iverson Genetic Diagnostics, Inc. provides physicians with genetics-based testing to identify individual patients' predispositions to major diseases as well as the therapeutic considerations that can improve treatment outcomes and quality of life.
With its growing portfolio of genetics-based tests and assays, the company is addressing one of today's major medical challenges by ushering in a new era of more timely, predictive, and affordable "personalized" healthcare.  The Company markets the Warfarin GenoSTAT Test® to provide personalized genetic profiles of patients' potential responses to treatment with warfarin.  Iverson Genetic Diagnostics is headquartered in Bothell, Washington, part of the greater Seattle technology corridor.  The company's facilities are CLIA- and CAP-certified.  
'/>"/>

SOURCE Iverson Genetic Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genetic information personalizes warfarin prescribing
2. WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. RAND study finds increase in piracy and terrorism at sea
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
7. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
8. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
9. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
10. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
11. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... BUENA, N.J. , Nov. 24, 2014  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... submissions in 2014 to seven, with eighteen submissions now ... Grenfell-Gardner , President and CEO of the Company, commented, ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
(Date:11/24/2014)... 2014   First ... Elsevier , a world-leading provider of scientific, ... announce the launch of the latest title in the ... in Food Science . ... a new platform to keep up-to-date with the expanding volume ...
Breaking Biology Technology:La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... Inclinix, Inc. has announced today that it has ... (Nasdaq: DATA ) to offer the most ... device companies globally. , ... DATATRAK,s eClinical(TM) platform to enhance its services as a ...
... Md., April 30 /PRNewswire/ -- ... company developing novel, proprietary antibodies for the treatment of ... will host a conference call and audio webcast on ... (3:00 pm Central European Time) to discuss its financial ...
... Inc. (NASDAQ: AEZS , TSX: AEZ), a ... will announce its first quarter 2009 financial and operating ... The Company will host a conference call and webcast ... 3:30 p.m., Eastern Time. , Participants may access the ...
Cached Biology Technology:DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 2DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 3DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 4Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 2Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 3Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 4
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)... Lithuania , Nov. 4, 2014   ... technologies, today announced that the latest version of ... in the Ongoing MINEX evaluation organized ... of fingerprint algorithms using the INCITS 378 fingerprint ... mandatory requirement in public tenders in ...
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... Studies on genetically engineered mice show that social stress ... atherosclerosis. Commonly used drugs to reduce blood pressure, however, ... a thesis presented at the University of Gothenburg, Sweden. ... is a correlation between psychosocial stress and the risk ...
... heart defects has been identified by a team of scientists, ... to new treatments for those affected by the conditions brought ... on identifying and studying the gene in zebrafish embryos, and ... studying the genetics of mice and people. "This ...
... 6, 2010 Parascript, LLC, the image analysis ... its Signature Xpert was awarded best performance ... Conference on Frontiers in Handwriting Recognition (ICFHR2010) in ... Parascript was among seven participants representing a total ...
Cached Biology News:Social stress leads to atherosclerosis 2Scientists find gene linked to congenital heart defect 2Scientists find gene linked to congenital heart defect 3Scientists find gene linked to congenital heart defect 4Parascript SignatureXpert Wins Forensic Signature Verification Competition 2
Designed for flow cytometric applications intended to identify...
MOUSE ANTI RAT RT1Bu / MOUSE Ia:BIOTIN Immunogen: Rat thymocyte membrane glycoproteins...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
Biology Products: